You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 5,939,318


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 5,939,318
Title: Cholesterol disposal fusion enzymes
Abstract:Fusion enzymes having multiple segments of different biological activity including one segment having P450scc activity and at least one segment having electron-transfer activity for transferring electrons to P450scc are described along with genetic constructs for production of such enzymes and methods for their use. Methods for their use include cholesterol degradation in vitro or in vivo as well as conversion of cholesterol to other useful steroidal products including pregnenolone.
Inventor(s): Miller; Walter L. (San Francisco, CA), Harikrishna; Jennifer A. (Kuala Lumpur, MY), Black; Stephen M. (Concord, CA)
Assignee: Regents of the University of California (Oakland, CA)
Application Number:08/564,090
Patent Claims:1. A polynucleotide sequence encoding a fusion enzyme, having an N-terminal and a C-terminal end, comprising (1) P450scc or a fragment thereof retaining cholesterol-side-chain-cleavage activity and (2) an electron-transfer protein having the ability to transfer electrons to said p450ssc.

2. The polynucleotide sequence of claim 1, wherein the electron-transfer protein is selected from the group consisting of adrenodoxin reductase, adrenodoxin, P450 oxidoreductase, cytochrome b5, and fragments thereof retaining ability to transfer electrons to said p450ssc.

3. The polynucleotide sequence of claim 1, wherein the sequence encoding P450scc has at least 90% sequence identity with the sequence encoding amino acids 40 to 521 of human P450scc (SEQ ID NO: 1) set forth in FIG. 1 and encodes a polypeptide having P450 side chain cleaving activity.

4. The polynucleotide sequence of claim 3, wherein the P450scc is encoded by the sequence of human P450scc (SEQ ID NO: 1) set forth in FIG. 1.

5. The polynucleotide sequence of claim 2, wherein the adrenodoxin reductase has at least 90% sequence identity with the amino acid sequence of human adrenodoxin reductase (SEQ ID NO: 3) from amino acids 33 to 497, excluding amino acids 204 to 209, set forth in FIG. 2.

6. The polynucleotide sequence of claim 5, wherein the adrenodoxin reductase is encoded by the sequence of human adrenodoxin reductase (SEQ ID NO: 3) excluding the sequence encoding amino acids 204 to 209 set forth in FIG. 2.

7. The polynucleotide sequence of claim 2, wherein the sequence encoding adrenodoxin has at least 90% sequence identity with the sequence (SEQ ID NO: 5) encoding amino acids 57 to 170 set forth in FIG. 3 and encodes a polypeptide having adrenodoxin electron-transfer activity.

8. The polynucleotide sequence of claim 7, wherein sequence encoding adrenodoxin is identical to the sequence encoding human adrenodoxin (SEQ ID NO: 5) from amino acid 57 to 170 set forth in FIG. 3.

9. The polynucleotide sequence of claim 2, wherein the protein sequences are comprised of sequences from bovine sources.

10. The polynucleotide sequence of claim 1, which further comprises a sequence encoding a linking peptide that links said P450scc or a fragment thereof retaining cholesterol-side-chain-cleaving activity to the electron-transfer protein.

11. The polynucleotide sequence of claim 2, wherein the electron-transfer protein comprises (1) adrenodoxin or a fragment thereof and (2) adrenodoxin reductase or a fragment thereof.

12. The polynucleotide sequence of claim 1, wherein P450scc or a fragment thereof retaining cholesterol-side-chain-cleaving activity is at the N-terminal end.

13. The polynucleotide sequence of claim 1, which further comprises a sequence encoding a signal peptide fused to the N-terminal of the fusion enzyme.

14. The polynucleotide sequence of claim 13, wherein the signal peptide is a mitochondrial-targeting signal peptide.

15. The polynucleotide sequence of claim 2, wherein adrenodoxin or a format thereof is at the C-terminal end.

16. The polynucleotide sequence of claim 10, wherein a linking peptide links said P450scc or a fragment thereof retaining cholesterol-side-chain-cleaving activity to adrenodoxin or a fragment thereof or to adrenodoxin reductase or a fragment thereof, or wherein a linking peptide links adrenodoxin or a fragment thereof to adrenodoxin reductase or a fragment thereof.

17. The polynucleotide sequence of claim 16, wherein any one or more of the linking peptides are Thr-Asp-Gly-Thr-Ser (SEQ ID NO: 9) or Thr-Asp-Gly-Ala-Ser (SEQ ID NO: 10).

18. The polynucleotide sequence of claim 11, wherein said sequence contains at least one codon different from a corresponding codon in a naturally occurring sequence.

19. A functional polynucleotide construct comprising (a) a transcription initiation region functional in a unicellular organism, (b) a polynucleotide sequence of claim 1, and (c) a transcription termination region, wherein expression of said construct in said unicellular organism results in production of the fusion enzyme encoded by said polynucleotide sequence.

20. The functional polynucleotide construct of claim 19, selected from plasmids F1, F2, F3, F4, F1AR+, and F2AR+.

21. The functional polynucleotide construct of claim 19 which further comprises an intron.

22. A procaryotic or eukaryotic host cell comprising a polynucleotide construct of claim 19.

Details for Patent 5,939,318

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 06/04/1986 ⤷  Try a Trial 2013-06-09
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 ⤷  Try a Trial 2013-06-09
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b Injection 103132 ⤷  Try a Trial 2013-06-09
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.